Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.90 USD
Change Today +0.77 / 24.60%
Volume 122.2K
AMBS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

amarantus bioscience holding (AMBS) Snapshot

Open
$3.15
Previous Close
$3.13
Day High
$4.24
Day Low
$3.15
52 Week High
08/5/14 - $20.70
52 Week Low
07/31/15 - $2.60
Market Cap
28.0M
Average Volume 10 Days
103.0K
EPS TTM
$-4.48
Shares Outstanding
7.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARANTUS BIOSCIENCE HOLDING (AMBS)

Related News

No related news articles were found.

amarantus bioscience holding (AMBS) Related Businessweek News

No Related Businessweek News Found

amarantus bioscience holding (AMBS) Details

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostics and therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, and ophthalmological disorders. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. Its therapeutic products in development comprise Eltoprazine, a small molecule drug that is in Phase II clinical trials for the treatment of Parkinson’s disease Levadopa-Induced Dyskinesia and adult attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including iretinitis pigmentosa, Parkinson’s disease, cardiac ischemia, and stroke. It is also developing NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

10 Employees
Last Reported Date: 04/6/15
Founded in 2008

amarantus bioscience holding (AMBS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $220.6K
Chief Financial Officer
Total Annual Compensation: $175.0K
Vice President of Financial Operations, Treas...
Total Annual Compensation: $138.3K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $126.0K
Compensation as of Fiscal Year 2014.

amarantus bioscience holding (AMBS) Key Developments

Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds

Amarantus BioScience Holdings Inc. announced the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) and Rutgers, The State University of New Jersey (Rutgers University) to expand the development of Amarantus' autologous full thickness skin replacement product, Engineered Skin Substitute (ESS), for the treatment of deep partial- and full-thickness burn wounds in adult patients. Amarantus is developing ESS for the treatment of severe burns and is preparing to commence Phase 2 clinical studies in the third quarter of 2015. ESS has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting, and has an open corporate-sponsored IND under which the clinical study can proceed.

Amarantus Bioscience Holdings, Inc Proposes Amendment to its Articles of Incorporation

Amarantus Bioscience Holdings Inc. announced that at its AGM to be held on August 3, 2015, the company has proposed to approve amendment to the company’s articles of incorporation to increase the company’s authorized shares of common stock from 13,333,334 to 35,000,000.

Amarantus Bioscience Holdings, Inc, Annual General Meeting, Aug 03, 2015

Amarantus Bioscience Holdings, Inc, Annual General Meeting, Aug 03, 2015., at 10:30 US Eastern Standard Time. Location: The NASDAQ MarketSite. Agenda: To elect the seven director nominees named in the proxy statement to hold office until the next annual meeting of stockholders; to ratify the appointment of Marcum LLP as the company’s independent auditors for the fiscal year ending December 31, 2015; to approve an amendment to the company’s articles of incorporation to increase the company’s authorized shares of common stock from 13,333,334 to 35,000,000; and to act on such other matters as may properly come before the meeting or any adjournment thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBS:US $3.90 USD +0.77

AMBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMBS.
View Industry Companies
 

Industry Analysis

AMBS

Industry Average

Valuation AMBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARANTUS BIOSCIENCE HOLDING, please visit www.amarantus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.